Oncocyte To Announce Second Quarter 2023 Financial Results

Conference Call and Webcast on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET

IRVINE, CA / ACCESSWIRE / August 3, 2023 / Oncocyte Corporation (NASDAQ: OCX), a precision diagnostics company, announced today that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, prior to the U.S. market open. The company will host a conference call and webcast on Thursday, August 10, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its financial results and recent highlights.

Interested parties may access the live call via telephone by dialing (877) 317-6789 for domestic callers and (412) 317-6789 for international callers. Once dialed in ask to be joined to the Oncocyte Corporation call.

The live webinar of the call may be accessed by visiting the "Events & Presentation" section of the Company's website at https://investors.oncocyte.com. A replay of the webinar will be available on the Company's website shortly after the conclusion of the call. 

About Oncocyte
Oncocyte is a precision diagnostics company. The Company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft" is a blood-based solid organ transplantation monitoring test, DetermaIO" is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies, and the pipeline test DetermaCNI" is blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information, visit https://oncocyte.com/

VitaGraft", DetermaIO", and DetermaCNI" are trademarks of Oncocyte Corporation.

CONTACT:
Stephanie Prince
PCG Advisory
(646) 863-6341
[email protected]

SOURCE: Oncocyte
via PRISM Mediawire, LLC

You May Also Be Interested In

• Gelato Strain Guide Examines Numbered Cuts, Reported Lineage and Historical Lab Data
• Can broadening earnings growth sustain the equity upcycle? JPM weighs in
• eBay named Morgan Stanley top pick on live commerce flywheel; stock surges